Abstract 15786: Long-Term Statin Persistence is Poor Among High-Risk Patients in a Real-World Administrative Claims Analysis
Introduction: A decade ago, statin persistence was <50% after 1 year, and recent short-term analyses have revealed very little progress in improving statin persistence, even in patients with a prior CV event. Data on longer-term statin persistence are lacking.
Objective: To analyze long-term, real-world data on statin persistence in patients with high CV risk.
Methods: This retrospective administrative claims analysis of the Optum Research Database included patients aged ≥45 years with diabetes and/or ASCVD who had a statin prescription filled in 2010, and included an analytic cohort of patients with an index date in 2010 and TG ≥150 mg/dL and a propensity-matched comparator cohort with TG <150 mg/dL and HDL-C >40 mg/dL; both cohorts were followed for ≥6 months up to March 2016.
Results: In the analytic cohort (n=23,181) and matched comparator cohort (n=23,181), respectively, mean (SD) age was 62.2 (9.6) and 62.6 (9.9) years, 49.7% and 49.5% were female, and mean follow-up was 41.4 (23.7) and 42.5 (23.9) months. Mean (SD) time to statin discontinuation was similar: 10.4 (13.1) months in the analytic cohort and 10.3 (13.1) months in the comparison cohort, and less than 20% of patients remained on statins by year 5 in both cohorts (Figure). Of patients who discontinued statins, 55.6% of the analytic and 56.7% of the comparison cohort did so within the first 6 months. The probability of remaining on statins after 1 year was 47% in both cohorts. Mean (SD) proportion of days covered for statins was 0.77 (0.26) in both cohorts at 6 months. This study describes new long-term data on statin persistence and confirms that poor statin persistence remains an issue of great concern for patients with high CV risk, including those with elevated TG who may be at higher CV risk. This underscores the urgency of developing public health programs and nationwide patient education about the well-defined benefits of statin therapy in the high-risk setting.
Funding: Amarin Pharma Inc.
- Cardiovascular disease
- Cholesterol-lowering drugs
- Community interventions
Author Disclosures: P. Toth: Speakers Bureau; Significant; Amarin Pharma Inc., Amgen, Kowa, Regeneron, Sanofi. Consultant/Advisory Board; Modest; Amgen, Gemphire, Merck, Sanofi. Consultant/Advisory Board; Significant; Amarin Pharma Inc., Kowa, Regen. C. Granowitz: Employment; Significant; Amarin Pharma Inc.. Ownership Interest; Significant; Amarin Pharma Inc. M. Hull: Employment; Significant; Optum. D. Liassou: Employment; Significant; Optum. Other; Significant; Optum. A. Anderson: Employment; Modest; Optum. Other; Modest; Optum. S. Philip: Employment; Significant; Amarin Pharma Inc.. Ownership Interest; Significant; Amarin Pharma Inc..
- © 2017 by American Heart Association, Inc.